Serositis is a rare manifestation of chronic GvHD (cGvHD). No risk factors or laboratory changes associated with this syndrome have been recognized to date, and outcomes have not been described in a large series. We searched our institutional database for patients undergoing allogeneic hematopoietic cell transplant identified as having serositis or pericarditis. Laboratory studies from prior to diagnosis, at diagnosis and post diagnosis of serositis, as well as outcomes from invasive procedures were included. Twenty patients met criteria for cGvHD-associated serositis, and all but three patients had a prior diagnosis of cGvHD. Fifteen were male, and the complication occurred in the setting of immunosuppressant taper in 12 cases. Ten patients required invasive interventions, including pericardial window or stripping. A significant increase in blood monocytes and decrease in serum albumin were identified at diagnosis compared with pre-diagnosis. Out of 20 patients, 17 were treated with steroids, with 12 demonstrating a complete response. These data suggest that cGvHD-associated serositis occurs mainly in the setting of treated as opposed to de novo cGvHD and biomarkers associated with the syndrome include a decrease in albumin and an increase in absolute monocyte count. Outcome data from larger series are required to better understand the optimal management of this rare complication.
INTRODUCTION
Serositis is a recognized but rare manifestation of chronic GvHD (cGvHD). It is defined as inflammation of any of the serosal linings of the body, including the pleura, peritoneum and pericardium. 1 In the non-transplant setting, serosal inflammation can be caused by many different factors, including drugs, 2 infections, [3] [4] [5] exposure to ionizing radiation, 6, 7 hereditary conditions, 8, 9 autoimmune disorders 10 and malignant disease. [11] [12] [13] In the hematopoietic cell transplant (HCT) setting, serositis and pericardial effusions are seen as an 'other' manifestation in patients with established cGvHD and even in this setting attributing them to cGvHD is a diagnosis of exclusion.
14 They are an uncommon finding, and as such data regarding serositis is limited to case reports and a few small case series. [15] [16] [17] [18] [19] [20] Little information exists regarding clinical, immunological or radiographic findings that proceed or accompany the onset of serositis associated with cGvHD. The responses to therapy and long-term outcomes of this chronic GvHD manifestation have also not been well described. Therefore, in order to better understand the prevalence, clinical features and outcomes of this rare condition, we performed a retrospective review of all patients receiving care after allogeneic HCT at our institution. In the following report, we describe the clinicopathological findings of 20 consecutive adult patients treated for chronic GvHD-associated serositis. To our knowledge, this is the largest case series of this complication reported to date.
PATIENTS AND METHODS Methods
We searched our institutional database for patients who had received care after allogeneic HCT between the years 1996 and 2013 and carried a diagnosis of serositis, pericardial effusion and/or pericarditis. These charts were then reviewed to confirm that the effusions could be considered secondary to chronic GvHD as per criteria below. For patients meeting the criteria, data were extracted by research staff according to pre-defined forms for variables of interest listed under clinicopathological data. Patients served as their own controls, and values of interest were also collected from 1 month prior to the onset of symptoms and 1 month after resolution of symptoms where available. Approval for the retrospective review of these records was obtained from the OHSU Institutional Review Board and was performed in accordance with the US federal regulations and the Declaration of Helsinki.
Patient characteristics
Patients were considered to have serositis if the presence of pleural effusions with or without pericardial effusion and/or ascites was confirmed by computed tomography scan. Pericardial effusions were defined as the presence of either a large or moderate effusion by either computed tomography scan or echocardiogram. Patients with smaller pericardial effusions were included if they had clinical signs or symptoms of pericarditis concurrently with their effusion including pericardial friction rubs, chest pain and diffuse PR interval depressions. Patients with ascites alone without other effusions were eliminated as it was difficult to determine whether isolated ascites was secondary to liver disease or true serositis. Patients deemed to have serositis secondary to other causes such as infection, malignancy, congestive heart failure (CHF) or nephrotic syndrome were excluded. Specifically, echocardiograms were reviewed to exclude patients with a reduced ejection fraction (EF) that would signify CHF and routine urinalyses (UAs) were reviewed to exclude patients with greater than 1+ protein which could be indicative of nephrotic syndrome.
Clinicopathological data
In order to identify clinical and pathological characteristics of chronic GvHD-associated serositis, we collected information associated with patients' transplant histories, including underlying hematologic malignancy, age at transplant, donor degree of match, type of transplant, conditioning regimen, history of acute or chronic GvHD prior to onset of serositis and pericarditis, and prior immunosuppressant therapy. Prior GvHD manifestations were defined based on National Institute of Health consensus (classic acute, late acute, overlap, chronic) along with specific organ manifestations (National Institute of Health consensus organ manifestation). As infectious etiologies had been previously reported as triggers for GvHD-associated pericarditis, we collected data on CMV, EBV, Human Herpes Virus 6 (HHV6) serologies and viral loads when available. For patients who underwent drainage of their effusions, cell counts and gram stains were reviewed if collected. To identify laboratory parameters that might be associated with the condition, we compared complete blood cell values and serum chemistries 1 month before, during and 1 month after the diagnosis of serositis and/or pericarditis where data was available.
We also recorded the results of serum cardiac biomarkers (troponin and brain natriuretic peptide), cardiac studies including electrocardiogram (EKG) and echocardiogram (ECHO), and imaging studies including computed tomography scans and chest X-rays obtained at the time of diagnosis.
Treatment and outcomes
Treatment for chronic GvHD-associated serositis included both medical and surgical interventions. We collected data including both type and dosage of immunosuppressant therapy employed, as well as surgical interventions and procedures required as part of the course of treatment. Overall survival was defined as the time from onset of serositis to the last follow-up or death from any cause. Partial response to therapy for serositis was defined as symptomatic improvement and reduction in effusion size as recorded in the medical records and as determined by examination and/or imaging. Complete response was defined as complete resolution of both symptoms of serositis as well as resolution of effusions by symptoms, examination and/or imaging.
Statistical analysis
Overall survival estimates were determined using the approach of Kaplan and Meier. Associations between categorical variables were determined by Fisher's exact test. Wilcoxon signed rank test was used to evaluate changes in continuous parameters before, during, and after the diagnosis of serositis and/or pericarditis. Correlations between continuous variables in were determined by Spearman's rho. All P-values represented were two-sided and statistical significance was declared at Po0.05.
RESULTS

Patient characteristics
From January 1996 to March 2013, 946 patients underwent allogeneic stem cell transplant at our institution. Prior to transplant, all patients underwent screening cardiac testing; none of the patients who subsequently developed pericarditis had cardiac abnormalities or pericardial effusions at baseline. We identified 28 cases in our database search, of which 20 (17 transplanted at OHSU, 3 outside institutions) met our inclusion criteria as having been diagnosed with cGvHD-associated serositis, making the incidence of this complication 1.8%. One hundred and eighty-seven patients died within the first 100 days of transplant, making the incidence of serositis 2.2% based upon a day +100 landmark. 8 of the initial 28 cases were ultimately excluded; one case associated with acute GvHD, two cases of anasarca without a clear evidence for serositis, one with pre-transplant pericarditis, one with malignant pericarditis and three who had received the majority of their care elsewhere and did not have sufficient data for analysis.
Characteristics of the patients included in this series are shown in Table 1 . Of the 20 who met the criteria for the study; 15 were men and 5 were women, resulting in a male to female ratio of 3:1. The median age at diagnosis was 42.5 years. The underlying diseases for which HCT was performed included AML (five patients), non-Hodgkin lymphoma (five patients), myelodysplastic syndrome (three patients), acute lymphoblastic leukemia (three patients), chronic myelogenous leukemia (two patients) and one each had multiple myeloma and prolymphocytic leukemia. All allografts were hematopoietic peripheral blood progenitor cell products obtained through apheresis. Eleven patients received their stem cells from a sibling, while nine underwent unrelated donor transplant. All but one was an 8/8 HLA-A, B, C, DR matched transplant. Fifteen of the grafts were of male origin, while four were female and one was unknown (transplanted elsewhere). Of the 20 (65%) patients, 13 received a high-dose TBI-based conditioning regimen (with 56.8% of patients at our institution overall having TBI as part of their conditioning regimen) and the majority of patients received GvHD prophylaxis per our institutional protocol with cyclosporine+methotrexate and prednisone (cyclosporine IV every 12 h beginning day − 2 with levels biweekly and goal 200-300 ng/mL; methotrexate 15 mg/m 2 IV on day +1 and methotrexate 10 mg/m 2 IV on days +3 and +6, followed by methylprednisolone 0.5 mg/kg IV daily beginning day +7). Two of the 20 patients underwent DLI during their treatment course, both prior to the onset of serositis. The median day of diagnosis of the complication from transplant was 745 days post HCT. All but three of the patients who developed serositis had a prior diagnosis of chronic GvHD (see Table 2 ). Serositis arose in the setting of current or recent (within weeks) steroid taper for previously established cGvHD in 12 of the 20 cases with established GvHD, and in the setting of their prophylactic steroid taper in one of the three subjects with serositis as the de novo presentation of chronic GvHD. Other concurrent organ manifestations of chronic GvHD in this patient cohort included predominantly skin, liver and gut involvement.
Clinical and Radiographic Presentation
The most common clinical presentation was edema 65% and dyspnea 40% (See Table 2 ). Four patients presented with pleuritic chest pain, and five patients complained solely of fatigue. Fourteen patients presented with both pleural and pericardial effusions, while five presented with pericardial effusions only and one with pleural effusions only. Pericardial effusion was diagnosed by transthoracic echocardiogram in 17 of the 19 patients with pericarditis, while two were discovered incidentally by computed tomography scan. Other than for a single case in which diffuse PR depressions were present on EKG at the time of diagnosis, there were no EKG findings associated the onset of pericarditis nor did any patient have an elevated troponin or B-type natriuretic peptide (BNP).
Laboratory Parameters
We identified a significant increase in the absolute monocyte counts at the time of diagnosis as compared to the absolute monocyte counts prior to the onset of symptoms (median 1000 vs 500 cells/μL P = 0.0005). We also identified a significant decrease in serum albumin at the onset of symptoms as compared with serum albumin prior to the onset of symptoms (median 3.4 vs 2.8 μg/dL, P = 0.0001). In terms of viral serologies, 8 out of 20 patients had a history of prior CMV reactivation although none had active CMV viremia within the month prior to or at the time of presentation. One patient had a reactivation of herpes zoster the month prior to the onset of his pericarditis; however, serologies from his pericardial fluid did not show the presence of this virus at the time of presentation of pericarditis. Out of 20 patients, two were tested for HHV6 reactivation at the time of presentation; in neither patient was this positive. None of the 20 patients had a history of EBV reactivation.
Treatment and outcomes
The mainstay of treatment for pericarditis for patients in this series was high-dose steroids, with doses ranging from 0.5 mg/kg to 2 mg/kg/day. Three patients did not initially receive therapy; two cases were not initially recognized as GvHD-related pericarditis and one patient refused treatment with steroids. Of the 17 patients who were treated with steroids; 12 had a complete response to treatment. Three died during their initial presentation, two secondary to inability to control symptoms of GvHD and one from hemorrhagic pericarditis as a complication of pericardiocentesis. Other immunosuppressants that were added as steroid-sparing agents are detailed in Table 2 . Three patients underwent pericardiocentesis, and five required placement of a pericardial window either because of large primary effusion or tamponade physiology. For those patients for who underwent pericardiocentesis or pericardial window, there was no evidence of malignancy or infectious process by cytology, gram stain or culture. Two patients ultimately underwent pericardial stripping because of constrictive/restrictive physiology. Biopsies taken from the pericardial tissue showed fibrotic tissue with no evidence of an active inflammatory process.
The median survival for the entire cohort was 105 months. 11 patients died during the period of follow-up, with four ultimately dying directly from or as a consequence of chronic GvHD. Other causes of death included pneumonia (1), hemorrhagic pericarditis (1), multiorgan failure (2), myocardial infarction (1) and relapsed cancer (2) . Of those who died as a consequence of chronic GvHD, three deaths occurred during their hospitalization for pericarditis, either as a direct consequence of the pericarditis or from inability to control GvHD-related symptoms.
DISCUSSION
Serositis is an uncommon but severe manifestation of chronic GvHD. Although rare, identifying both clinical and laboratory findings that might herald its onset are important given the magnitude of the impact it can have on cardiopulmonary function. In this review, we were able to characterize common clinical features, explore risk factors, identify associated changes in serum chemistries and describe treatments and clinical outcomes. The incidence of serositis in our study was 1.8% (or 2.2% based upon a day +100 landmark recognizing early death as a competing risk for its development). This percentage is similar to the incidence reported by others, 0.99-2% in patients who had undergone allogeneic HCT, 16, 17, 21 although it is somewhat lower than the 4.4% incidence noted in the pediatric literature. 22 Of note we identified just one patient with pleural effusions as the primary location of serositis. It is likely that the incidence of serositis is actually higher as patients with pleural effusions only may not have been classified as having GVH-associated serositis as the differential for pleural effusions is quite large. Similar to other studies, we found that serositis tended to be a late complication of Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; HCT = hematopoietic stem cell transplant; MDS = myelodysplastic syndrome; MM = multiple myeloma; NHL = Non-Hodgkin's lymphoma.
Chronic GvHD-associated serositis and pericarditis JT Leonard et al GvHD rather than an early complication. 17 However, while serositis is considered only a manifestation of GvHD in patients with already established chronic GvHD, 14 we did identify three patients for whom it was a component of the initial presentation of their cGvHD.
The association between the onset of serositis and recent taper of immunosuppressive therapy, an association that was present in the majority of our patients, has not been previously reported. In several cases, steroid tapers were quite rapid, occurring in the setting of patients presenting with infection, steroid side effects, or due to patient non-compliance. In other cases, patients were undergoing immunosuppressive therapy (IST) taper in the setting of already present cGvHD. While the decision to taper immunosuppressive therapy should not be altered because of this rare complication, it does demonstrate the need for vigilance regarding not only the symptoms involving the initial organs involved with cGvHD but also for manifestations of new organ involvement as IST is tapered.
We identified potential patient characteristics associated with chronic GvHD-associated serositis in this series, including sex and conditioning regimen differences. The majority of patients we identified for this study were male, with a male-to-female ratio of 3:1. Interestingly, for patients who develop systemic lupus erythematosus in their later years, there is a male predominance and a higher incidence of serositis as a presenting symptom. 23 In addition, a prior study has noted that pericarditis as a presentation of AML has a strong male predominance.
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Although female-to-male HCT is a known risk factor for GvHD, the majority of donors in this series were male, making donor sex an unlikely cause of the male predominance seen in our series. Further studies addressing specific immunologic differences would be required to help determine gender-specific risk factors for this condition.
The conditioning regimen may play a role as a risk factor for serositis. Although about half of the patients at our institution undergoing allogeneic HCT receive total body irradiation (TBI) as part of their conditioning regimen, 65% of patients in this cohort were recipients of myeloablative TBI-based conditioning. This observation is in agreement with Cavet et al., 24 who described two cases of constrictive pericarditis in patients receiving TBI as part of their conditioning regimen. In that series, it was noted that constrictive pericarditis was also seen in patients who underwent thoracic radiotherapy for malignancy and suggested that pericarditis was secondary to radiation-induced pericardial damage. In our series only one of the 20 patients had thoracic radiation while for the remainder, their radiation exposure was limited to a TBIbased regimen. Rates of both acute and chronic GvHD have been reported as increased after TBI-based conditioning; 21 this could potentially be expanded to include an increased risk of serositis.
The majority of patients in this series were treated with highdose methylprednisolone, with doses ranging from 0.5-2 mg/kg. While in other case series a relatively benign clinical course was reported, 11 of our patients ultimately died, with three dying during their initial presentation with pericarditis, primarily from an inability to control GvHD symptoms (see Table 2 ). Two patients in our series ultimately required pericardial stripping because of the development of constrictive/restrictive physiology. Only two case reports have previously reported constrictive pericarditis secondary to GvHD; in the first both patients underwent pericardial striping while in the second the patient died prior to the procedure. 24, 25 Both patients in our series who underwent pericardial stripping did survive in the short term after the procedure. However, one of these patients ultimately died months later from infectious complications.
Prior studies have not evaluated laboratory findings prior to, during, and after an episode of serositis. We found a significant increase in the absolute serum monocyte count as well as a decrease in serum albumin at the time of presentation. Although the fall in serum albumin can likely be attributed to severe systemic illness as a negative acute phase reactant, the rise in serum monocytes is intriguing. As this was a retrospective study, we were not able to further characterize this cell population.
In conclusion, we have identified that serositis presents more typically as a late complication of chronic GvHD that can be seen in the context of IST taper for already present cGvHD. The most common clinical presentation noted was rapid weight gain and edema with common complaints of dyspnea on exertion. It is associated with an increase in relative monocyte count and a decrease in serum albumin at its onset. Risk factors may include male gender, ablative TBI-based conditioning regimens and recent IST taper. The mainstay of treatment is high-dose steroids, with the majority of patients responding to treatment. This study is limited by its retrospective nature and the lack of a control group and thus all conclusions are only descriptive in nature. Further studies are needed to better understand the interplay of immune mechanisms which lead to the development of GvHD-associated serositis as well as to understand the role of invasive procedures in this condition.
